(BUSINESS WIRE)– pSivida Corp. (NASDAQ:PSDV), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the sale of ILUVIEN® for diabetic macular edema (DME) has begun in Portugal. Also sold in the UK and Germany, ILUVIEN is indicated in the EU for treatment of vision impairment associated with chronic DME insufficiently responsive to available treatments… Read more »
Shares of pSivida Corp opened today at $4.02 and are currently trading up at $4.035. PSDV has a 1-year high of $5.45 and a 1-year low of $3.26. The stock’s 50-day moving average is $4.21 and it’s 200-day moving average is $4.24.
On the ratings front, pSivida Corp has been the subject of a number of recent research reports. In a report published on November 7, analyst Arlinda Lee from MLV & Co. reiterated a Buy rating on PSDV, with a price target of $6.50, which represents a potential upside of 61.7% from where the stock is currently trading. Separately, on September 29, Northland Securities` Suraj Kalia reiterated a Buy rating on pSivida Corp shares and has a price target of $10.
pSivida Corp develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years.